Cullinan Therapeutics Inc (CGEM) Stock Price, Quote & News

Company Profile

Cullinan Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops therapies for autoimmune diseases and cancer in the United States. The company develops zipalertinib, a bioavailable small molecule in Phase 3 trial for the treatment of patients with non-small cell lung cancer; CLN-978, a T cell engager to treat systemic lupus erythematosus and rheumatoid arthritis; and CLN-619, a monoclonal antibody in Phase 1 trial for the treatment of solid tumors and multiple myeloma. Its deve...

Industry: Biotechnology

Sector: Healthcare

Phone: 617 410 4650

Website: cullinantherapeutics.com

Address:

One Main Street, Suite 1350, Cambridge, United States

aletz Mar. 12 at 1:47 PM

$CGEM https://www.biostockinfo.com/t-cell-engagers-tce-the-race-to-reset-the-immune-system-and-the-biotechs-positioning-to-win/ This article explains what TCE is about and how CGEM is preparing for the new trend

0 · Reply

StocktwitsEarnings Mar. 10 at 3:30 PM

$CGEM Q4 '25 Earnings Results & Recap Cullinan expects its current cash, cash equivalents, investments, and interest receivable of $377.9M and $61.1M, respectively, to fund operations into 2029, based on current operational plans.

0 · Reply

rain____ Mar. 9 at 2:24 AM

$CGEM .....................

0 · Reply

HighRegard Mar. 5 at 3:18 AM

$CGEM this is trending nicely with solid price targets from analusts and recetnly citi. Also off the radar from worlds tormoil and largely saw very little negativity affeting the wider market and larger caps. been in since $10 and will think about $30 partial exit ...bullish. Keep eyes on news coming out about continuing progress and potential

0 · Reply

OfficialStocktwitsUser Mar. 3 at 1:06 AM

$CGEM RSI: 85.74, MACD: 1.0101 Vol: 1.37, MA20: 13.15, MA50: 11.76 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

0 · Reply

JFais Mar. 2 at 8:25 PM

$CGEM seems not to care what's going on at the FDA given its clear path to market Prior approvals in AML show 20% to 30% CR/CRh with duration of 4 to 6 months FLT3 T-cell engager already showing on the high end (in heavily pretreated patients no less, similar goes for p53)

0 · Reply

JFais Mar. 2 at 8:23 PM

$CGEM seems not to care what's going on at the FDA given its clear path to market Prior approvals in AML show 20% to 30% CR/CRh with duration of 4 to 6 months FLT3 T-cell engager already showing on the high end of (in heavily pretreated patients no less, same goes for p53)

0 · Reply

JFais Mar. 2 at 8:08 PM

$CGEM seems not to care what's going on at the FDA Prior approvals in AML show 20% to 30% CR/CRh with duration of 4 to 6 months in single arm studies FLT3 T-cell engager already showing on the high end of that (in heavily pretreated patients no less, same goes for p53 subset)

0 · Reply

Nosh Feb. 27 at 10:01 PM

$CGEM Added $15.50 area...the fade but still up in this tape? Slowly building this one out.

1 · Reply

JFais Feb. 27 at 4:24 PM

$CGEM

0 · Reply

Cullinan Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2025 Financial Results

Feb 24, 2026, 7:00 AM EST - 20 days ago

Cullinan Therapeutics to Participate in Upcoming Investor Conferences

Feb 23, 2026, 5:39 PM EST - 21 days ago

Cullinan Therapeutics: Thesis Strengthening For This T-Cell Engager Specialist

Feb 19, 2026, 4:05 PM EST - 25 days ago

Cullinan Therapeutics, Inc. (CGEM) Presents at Citi's 2026 Virtual Oncology Leadership Summit Transcript

Feb 18, 2026, 7:00 AM EST - 26 days ago

Cullinan Therapeutics to Participate in Fireside Chat at the Citi 2026 Virtual Oncology Leadership Summit

Feb 5, 2026, 7:00 AM EST - 5 weeks ago

Cullinan Therapeutics to Participate in Fireside Chat at the Guggenheim Emerging Outlook: Biotech Summit 2026

Jan 28, 2026, 11:03 PM EST - 6 weeks ago

Cullinan Therapeutics: Cash-Rich Biotech With Multiple Value Drivers

Jan 8, 2026, 7:00 AM EST - 2 months ago

Cullinan Therapeutics Provides Corporate Update and Highlights Anticipated 2026 Milestones

Dec 9, 2025, 4:37 AM EST - 3 months ago

Cullinan Therapeutics, Inc. (CGEM) Discusses Initial CLN-049 Results and Development Strategy for AML Applications Transcript

Dec 8, 2025, 10:31 AM EST - 3 months ago

Cullinan Therapeutics Showcases Compelling Clinical Data in AML for CLN-049, Novel FLT3xCD3 T Cell Engager, in Oral Presentation at the 67th ASH Meeting

$Cullinan Therapeutics Receives FDA Fast Track Designation for CLN-049, a Novel FLT3xCD3 T Cell Engager, in Relapsed/Refractory Acute Myeloid Leukemia$

Dec 1, 2025, 7:00 AM EST - 3 months ago

Cullinan Therapeutics Receives FDA Fast Track Designation for CLN-049, a Novel FLT3xCD3 T Cell Engager, in Relapsed/Refractory Acute Myeloid Leukemia

Nov 20, 2025, 7:00 AM EST - 4 months ago

Taiho Oncology, Taiho Pharmaceutical and Cullinan Therapeutics Initiate Rolling Submission of New Drug Application to U.S. Food and Drug Administration for Zipalertinib for Treatment of Locally Advanced or Metastatic Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations

Nov 10, 2025, 7:00 AM EST - 4 months ago

Cullinan Therapeutics to Participate in Upcoming Investor Conferences and Host Analyst and Investor Event at 2025 ASH Annual Meeting

Nov 6, 2025, 7:00 AM EST - 4 months ago

Cullinan Therapeutics Provides Corporate Update and Reports Third Quarter 2025 Financial Results

Nov 3, 2025, 9:11 AM EST - 4 months ago

Cullinan Therapeutics to Showcase New Data Demonstrating Compelling Clinical Activity for CLN-049, a Novel FLT3xCD3 T Cell Engager, in AML Patients in an Oral Presentation at the 67th ASH Annual Meeting

Oct 25, 2025, 11:01 AM EDT - 5 months ago

Cullinan Therapeutics Shares Additional Preclinical B Cell Depletion Data for CLN-978, Supporting Clinical Development Across Multiple Autoimmune Diseases, at ACR Convergence 2025

Oct 17, 2025, 7:01 AM EDT - 5 months ago

Cullinan Therapeutics: Worthy Of A Small Position

Oct 13, 2025, 12:46 PM EDT - 5 months ago

Cullinan Therapeutics Cancer Drug Shows Efficacy In Brain Metastases Among Lung Cancer Patients With Certain Mutations

Oct 12, 2025, 6:27 PM EDT - 5 months ago

Taiho Oncology and Cullinan Therapeutics Present Data on Zipalertinib in Patients with NSCLC with EGFR mutations and Active Brain Metastases at the ESMO Congress 2025

Sep 12, 2025, 7:00 AM EDT - 6 months ago

Cullinan Therapeutics to Participate in Fireside Chat at the Stifel 2025 Virtual Immunology and Inflammation Forum

Sep 10, 2025, 10:50 AM EDT - 6 months ago

Cullinan Therapeutics, Inc. (CGEM) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Sep 9, 2025, 5:30 AM EDT - 6 months ago

Taiho Oncology and Cullinan Therapeutics Present Data on Zipalertinib at the IASLC 2025 World Conference on Lung Cancer

Aug 7, 2025, 7:00 AM EDT - 7 months ago

Cullinan Therapeutics Provides Corporate Update and Reports Second Quarter 2025 Financial Results

Jul 15, 2025, 10:24 PM EDT - 8 months ago

Cullinan Therapeutics: Betting On Zipalertinib NDA Catalyst

Jun 4, 2025, 4:02 PM EDT - 10 months ago

Cullinan Therapeutics Licenses Rights to Velinotamig, a Clinical-Stage BCMA-Directed Bispecific T Cell Engager, from Genrix Bio for Development in Autoimmune Diseases

Jun 1, 2025, 8:21 AM EDT - 10 months ago

Taiho Oncology and Cullinan Therapeutics Announce Pivotal REZILIENT1 Phase 1/2 Data Published in the Journal of Clinical Oncology

May 29, 2025, 7:00 AM EDT - 10 months ago

Cullinan Therapeutics to Host Analyst and Investor Event at 2025 ASCO Annual Meeting and Participate in Jefferies 2025 Global Healthcare Conference

May 22, 2025, 5:15 PM EDT - 10 months ago

Cullinan Therapeutics, Taiho Pharmaceutical, and Taiho Oncology to Present Positive Results from Pivotal Phase 2b REZILIENT1 Trial of Zipalertinib at ASCO 2025

May 8, 2025, 7:00 AM EDT - 11 months ago

Cullinan Therapeutics Provides Corporate Update and Reports First Quarter 2025 Financial Results

Apr 29, 2025, 7:00 AM EDT - 11 months ago

Cullinan Therapeutics to Initiate Study of CLN-978, a Bispecific CD19 T Cell Engager Administered Subcutaneously, in Patients with Sjögren's Disease in the United States

Apr 23, 2025, 10:14 AM EDT - 11 months ago

Cullinan Therapeutics to Present Results from REZILIENT1, a Phase 1/2 Trial of Zipalertinib in Patients with Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations Who Have Received Prior Therapy, at ASCO 2025

Apr 16, 2025, 7:00 AM EDT - 11 months ago

Cullinan Therapeutics Receives Approval from European Medicines Agency to Initiate Phase 1 Trial of CLN-978, a Bispecific CD19 T Cell Engager Administered Subcutaneously, in Patients with Rheumatoid Arthritis

Feb 27, 2025, 7:00 AM EST - 1 year ago

Cullinan Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2024 Financial Results

Jan 28, 2025, 7:00 PM EST - 1 year ago

Taiho Pharmaceutical, Taiho Oncology, and Cullinan Therapeutics Announce Primary Endpoint Met in Phase 2b Trial of Zipalertinib in Patients with Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations Who Have Received Prior Therapy

Jan 9, 2025, 11:11 PM EST - 1 year ago

Cullinan Therapeutics' CLN-978 And Zipalertinib Look Promising In NSCLC

Jan 8, 2025, 5:26 PM EST - 1 year ago

Cullinan Therapeutics: Casting A Wide Net With Their Pipeline

Nov 14, 2024, 10:01 AM EST - 1 year ago

Cullinan Therapeutics Announces Preclinical Data for CLN-978, a CD19-directed T Cell Engager, to be Presented at ACR Convergence 2024

Nov 5, 2024, 7:00 AM EST - 1 year ago

Cullinan Therapeutics to Participate in Fireside Chat at Stifel 2024 Healthcare Conference

Nov 4, 2024, 7:00 AM EST - 1 year ago

Cullinan Therapeutics to Present Preclinical Data for CLN-978, a CD19-directed T Cell Engager, at ACR Convergence 2024

Oct 16, 2024, 7:00 AM EDT - 1 year ago

Cullinan Therapeutics Receives U.S. FDA Clearance of Investigational New Drug Application for CLN-978 Administered Subcutaneously in Patients with Moderate to Severe Systemic Lupus Erythematosus

Sep 17, 2024, 7:00 AM EDT - 1 year ago

Cullinan Therapeutics Receives Approval to Initiate its Global Phase 1 Clinical Trial of CLN-978 for the Treatment of Systemic Lupus Erythematosus

Sep 14, 2024, 4:15 AM EDT - 1 year ago

Cullinan Therapeutics Presents Positive Updated Data from Module C of Zipalertinib Pivotal Phase 2b Study at ESMO 2024

Jun 1, 2024, 7:00 AM EDT - 1 year ago

Cullinan Therapeutics Announces Positive Initial Data from Pivotal Phase 2b REZILIENT1 Study of Zipalertinib

May 24, 2024, 8:00 AM EDT - 1 year ago

Cullinan Therapeutics to Participate in Fireside Chat at TD Cowen 5th Annual Oncology Innovation Summit

May 23, 2024, 5:04 PM EDT - 1 year ago

Cullinan Therapeutics to Present First Data for CLN-619, a Novel Anti-MICA/B Antibody, in Combination with a Checkpoint Inhibitor and Updated Monotherapy Data at ASCO 2024

May 15, 2024, 4:05 PM EDT - 1 year ago

Cullinan Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results

Apr 29, 2024, 7:00 AM EDT - 2 years ago

Cullinan Therapeutics Announces Appointment of Mary Kay Fenton as Chief Financial Officer

Apr 24, 2024, 10:09 AM EDT - 2 years ago

Cullinan Therapeutics to Present Clinical Data from Phase 1 Study Evaluating Novel Anti-MICA/B Antibody, CLN-619, as Monotherapy and in Combination with a Checkpoint Inhibitor in Patients with Advanced Solid Tumors at ASCO 2024

Apr 16, 2024, 7:00 AM EDT - 2 years ago

Cullinan Therapeutics Announces Strategic Expansion into Autoimmune Diseases

Apr 16, 2024, 6:59 AM EDT - 2 years ago

Cullinan Therapeutics Announces Oversubscribed $280 million Private Placement

aletz Mar. 12 at 1:47 PM

0 · Reply

StocktwitsEarnings Mar. 10 at 3:30 PM

0 · Reply

rain____ Mar. 9 at 2:24 AM

$CGEM .....................

0 · Reply

HighRegard Mar. 5 at 3:18 AM

0 · Reply

OfficialStocktwitsUser Mar. 3 at 1:06 AM

0 · Reply

JFais Mar. 2 at 8:25 PM

0 · Reply

JFais Mar. 2 at 8:23 PM

$CGEM seems not to care what's going on at the FDA given its clear path to market Prior approvals in AML show 20% to 30% CR/CRh with duration of 4 to 6 months FLT3 T-cell engager already showing on the high end of (in heavily pretreated patients no less, same goes for p53)

0 · Reply

JFais Mar. 2 at 8:08 PM

0 · Reply

Nosh Feb. 27 at 10:01 PM

$CGEM Added $15.50 area...the fade but still up in this tape? Slowly building this one out.

1 · Reply

JFais Feb. 27 at 4:24 PM

$CGEM

0 · Reply

JFais Feb. 27 at 4:22 PM

$CGEM- lucky timing, but I'll take it $NUVB

0 · Reply

DeadManJoaquin Feb. 27 at 4:01 PM

$CGEM I think this one has 10x on it 2 years. Worth a flutter.

2 · Reply

kubota2323 Feb. 25 at 3:55 PM

$CLYM $CGEM $ZBIO $NVS $SNY giddy up

0 · Reply

AlphaAlpaca Feb. 24 at 3:05 PM

$CGEM Took a position here today, under the radar biotech flush with cash and nice catalysts for this year. Solid momentum and trending well. The Alpaca holding strong 💪

0 · Reply

JFais Feb. 24 at 12:37 PM

$CGEM - SoC for TP53 AML (all lines of therapy) is clinical trial. Would be a W for these patients if 30%+ CR holds up For my position at least, FLT3 is the center of thesis & autoimmune efforts a nice kicker/call option

0 · Reply

Retail_Contrarian Feb. 24 at 12:16 AM

$CGEM Sentiment climbing. Nice uptrend! 👀

0 · Reply

JFais Feb. 23 at 10:41 PM

$CGEM (L) Cullinan Therapeutics: Thesis Strengthening For This T-Cell Engager Specialist https://seekingalpha.com/article/4873592?gt=f115d339583c7609

1 · Reply

BillionerOfKing Feb. 21 at 10:47 AM

$CGEM Current Stock Price: $13.65 Contracts to trade: $14.0 CGEM Mar 20 2026 Call Entry: $1.00 Exit: $1.58 ROI: 58% Hold ~31 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts

0 · Reply

metalcook Feb. 20 at 3:08 PM

$CGEM totally under the radar of retail What's impressive is that they rebranded 2y ago to become an I&I Biotech way from cancer. During citi oncology townhall yesterday, it seems they are back an oncology play with CLN-049 promise (data probably at ASCO june) and zipartinib imminent completion of nda submission. I&I has returned to the background. Results expected around April-MAY

0 · Reply

Retail_Contrarian Feb. 20 at 2:18 AM

$CGEM 🤔👀💸🍻🤣

0 · Reply

outlawinvestor1 Feb. 19 at 10:34 PM

$CGEM people finally starting to pay attention. at $740M mc with $430M cash, this one is still wildly undervalued. the trick is to discover these gems before the ib analysts start noticing the value.

0 · Reply

JFais Feb. 19 at 9:32 PM

$CGEM (L) Posted Citi notes in Chat Good example of what I look for in clinical-stage biotech these days $XBI Steady stream of data this year and next (helps me stay patient), multiple high value shots on goal, clear path to market, strong balance sheet + degree of downside cushion & BD-savvy mgmt

1 · Reply

Market Cap	796.94M
Revenue (ttm)	0.00
Net Income (ttm)	-167.38M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	670,714
Avg Vol	763,178
Day's Range	N/A - N/A
Shares Out	59.08M
Stochastic %K	11%
Beta	-0.15
Analysts	Strong Sell
Price Target	$32.00